Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study-Reference-Cited by-同舟云学术

Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study

Published:2024-09-11 Issue:1 Volume:24 Page:
ISSN:1471-230X
Container-title:BMC Gastroenterology
language:en
Short-container-title:BMC Gastroenterol

Author:

Na Ji Eun,Park Yong Eun,Park Jongha,Kim Tae-Oh,Lee Jong Hoon,Park Su Bum,Kim Soyoung,Lee Seung Bum,

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12876-024-03403-8.pdf

Reference35 articles.

1. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.

2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet (London, England). 2002;359(9317):1541–9.

3. Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2021;54(10):1298–308.

4. Otake H, Matsumoto S, Mashima H. Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies. Intestinal research. 2022;20(4):464–74.

5. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375(20):1946–60.